PATH vs VXRT
Uipath Inc (PATH) versus Vaxart Inc (VXRT) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Vaxart Inc (VXRT) is a biotechnology company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported VXRT revenue for 2024-12-31 was $28.7M. Net income was -$66.9M. Revenue was up 288.9% from 2023-12-31 to 2024-12-31. VXRT currently screens at market cap $73.0M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. VXRT currently screens at market cap $73.0M.
Not investment advice. Open the PATH and VXRT stock pages for the full models.
Not investment advice.